BSX stock forecast, quote, news & analysis
Boston Scientific focuses on less invasive medical devices that are inserted into the human body through small openings or cuts... Show more
Boston Scientific (BSX) Stock Analysis: Guidance Cuts and Cybersecurity Fallout Pressure the Medtech Leader
Key Takeaways
- Boston Scientific shares traded near $42 in late October 2026, down roughly 4% over the trailing 30 days and roughly 60% below their November 2025 52-week high.
- Third-quarter 2026 net sales rose 1.5% to $5.14 billion, but GAAP EPS fell to $0.40 from $0.51 a year earlier and adjusted EPS declined to $0.73.
- Management trimmed its full-year outlook again, citing an August cybersecurity incident, and now projects about 4.25% reported sales growth with adjusted EPS of $3.16 to $3.18.
- Fourth-quarter guidance points to a 1% to 3% sales decline, signaling near-term operational headwinds as the company restores normal operations.
- Boston Scientific restructured into three reportable segments and appointed a new COO, while FDA clearances and a new clinical trial highlight an intact innovation pipeline.
- For additional detail on Boston Scientific's Price Targets, Earnings, and Forecast, explore the dedicated pages.
- Investors tracking momentum and AI-driven strategies can explore Trending AI Robots for curated, data-driven trading insights.
Current Market Snapshot
Boston Scientific Corporation (NYSE: BSX) enters the final stretch of 2026 under pressure. After trading above $100 as recently as late 2025, the stock has shed roughly 60% of its value and now changes hands near the low $40s. The shares have slipped about 4% over the past month, reflecting a challenging operating environment rather than a single isolated event.
The medical device sector has broadly held up, but Boston Scientific's specific headwinds—an August cybersecurity incident that disrupted operations across multiple divisions and a series of downward guidance revisions—have separated it from many peers. Analyst consensus remains in "buy" territory, yet investor sentiment has turned cautious as the company works to restore growth momentum.
Boston Scientific (BSX) Business Overview and Competitive Position
Boston Scientific is a global medical technology company headquartered in Marlborough, Massachusetts. Founded in 1979, the company develops and manufactures devices used to diagnose and treat cardiovascular, respiratory, digestive, oncological, neurological, and urological conditions. Its portfolio is organized into two primary segments: Cardiovascular, which contributes roughly two-thirds of revenue, and MedSurg.
The company's competitive strengths include a broad, diversified product portfolio spanning cardiac rhythm management, electrophysiology, interventional cardiology, endoscopy, urology, and neuromodulation. Investors follow BSX closely because of its scale, its recurring revenue base, and its track record of innovation through clinical trials and regulatory clearances.
Recent Developments Driving BSX
Several verified developments have shaped Boston Scientific's stock over the past month. The most consequential was its third-quarter earnings report, which showed net sales of $5.14 billion, up 1.5% year over year, but declining profitability. GAAP net income fell to $582 million, or $0.40 per share, from $755 million, or $0.51 per share, a year earlier, while adjusted EPS slipped to $0.73 from $0.75.
Management again reduced full-year guidance, projecting about 4.25% reported sales growth and adjusted EPS of $3.16 to $3.18, down from a prior range of $3.28 to $3.32. Fourth-quarter sales are expected to decline 1% to 3%. The company attributed the reset largely to an August cybersecurity incident that disrupted electrophysiology, interventional cardiology, vascular, cardiac rhythm management, endoscopy, and urology operations.
Amid the recovery, Boston Scientific announced an organizational restructuring into three reportable segments and named Joseph M. Fitzgerald as Chief Operating Officer. On the product front, the company received FDA 510(k) clearances for its StoneSmart kidney stone technologies and an expanded SEISMIQ catheter size offering, and it began enrollment in the Elite AF atrial fibrillation trial. The stock has also drawn analyst attention, with Bernstein reiterating an Outperform rating, while insider purchases—including roughly $9 million in shares by CEO Mike Mahoney—signal confidence from leadership.
Trending AI Robots
Tickeron's Trending AI Robots page highlights a curated selection of AI-powered trading bots from a much larger universe. Tickeron offers hundreds of bots that collectively trade thousands of tickers, but only the top-performing and most relevant strategies appear in this section. The bots vary considerably in strategy, timeframe, and performance metrics, ranging from short-term swing systems to longer-horizon approaches, which allows traders to filter for signals that match their own risk tolerance and objectives. For investors looking to complement fundamental research with quantitative, rules-based signals, the page provides a useful starting point to monitor how automated strategies are positioning across the market.
2026 Outlook and What Investors Should Watch
Looking ahead, the key question for Boston Scientific is how quickly it can fully restore operations disrupted by the cybersecurity incident and return to more normalized growth. Investors should monitor whether fourth-quarter results land within the company's guided 1% to 3% sales decline, and whether management can stabilize its outlook heading into 2027.
Additional factors worth watching include the integration of the new three-segment operating structure, the commercial ramp of newly cleared products, and progress on the Elite AF clinical trial. Macroeconomic considerations, foreign currency fluctuations, and competitive dynamics across the electrophysiology and interventional cardiology markets will also influence the trajectory. The company's reduced guidance suggests near-term caution is warranted, but its broad portfolio and continued innovation provide a foundation for a potential recovery.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
BSX's Indicator enters downward trend
The Aroon Indicator for BSX entered a downward trend on October 14, 2026. Tickeron's A.I.dvisor identified a pattern where the AroonDown red line was above 70 while the AroonUp green line was below 30 for three straight days. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options. A.I.dvisor looked at 127 similar instances where the Aroon Indicator formed such a pattern. In 89 of the 127 cases the stock moved lower. This puts the odds of a downward move at 70%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 33 of 67 cases where BSX's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 49%.
The Momentum Indicator moved below the 0 level on October 28, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on BSX as a result. In 48 of 90 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 53%.
The Moving Average Convergence Divergence Histogram (MACD) for BSX turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In 28 of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at 62%.
BSX moved below its 50-day moving average on October 27, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BSX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 54%.
BSX broke above its upper Bollinger Band on October 19, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where BSX's RSI Indicator exited the oversold zone, 14 of 26 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 54%.
Following a +2.68% 3-day Advance, the price is estimated to grow further. Considering data from situations where BSX advanced for three days, in 199 of 335 cases, the price rose further within the following month. The odds of a continued upward trend are 59%.
Fundamental Analysis (Ratings)
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 55 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Price Growth Rating for this company is 64 (best 1 - 100 worst), indicating fairly steady price growth. BSX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 68 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (2.440) is normal, around the industry mean (4.209). P/E Ratio (16.859) is within average values for comparable stocks, (1.433). Projected Growth (PEG Ratio) (0.618) is also within normal values, averaging (11.253). Dividend Yield (0.000) settles around the average of (0.010) among similar stocks. P/S Ratio (3.117) is also within normal values, averaging (40.124).
The Tickeron PE Growth Rating for this company is 95 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BSX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
a maker of medical devices
Industry MedicalNursingServices